Dianthus Therapeutics, Inc. (DNTH) income statement
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$86.98−2.57 (-2.87%)
Close on Nov 17, 2026Market cap $4.87BP/E –Yield 0.00%
Dianthus Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -11592.7%
- Net margin
- -9927.5%
- Return on equity, FY2025
- -38.4%
Financial strength
- Current ratio
- 30.02
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 195.3%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.92
- Dividend yield
- 0.00%
See a number that looks wrong?